NCT05929313已完成不适用
A Prospective, Multicenter, Randomized Controlled, Non- Inferiority Trial to Evaluate the Effectiveness and Safety of the Scoreflex TRIO High-pressure Tri-wire Scoring Balloon Catheter for Balloon Dilatation of Coronary Artery Stenosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- OrbusNeich
- 入组人数
- 210
- 试验地点
- 4
- 主要终点
- Rate of device Procedural Success
研究概览
简要总结
To evaluate the acute safety and device procedural success of the Scoreflex TRIO Scoring PTCA catheters versus Scoreflex NC Scoring PTCA catheters in subjects with stenotic coronary arteries during percutaneous coronary intervention.
详细描述
This is a prospective, multi-center, open-label, non-inferiority, randomized controlled trial which plans to enroll 210 subjects. All subjects enrolled will be randomly assigned to the test group (n=105) and the control group (n=105). Subjects in the test group and the control group will receive Scoreflex TRIO Scoring PTCA catheters and Scoreflex NC Scoring PTCA catheters respectively.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 and≤
- •Volunteer to participate in this trial and provide the written informed consent.
- •Subjects must have a single or double vessel coronary artery disease (CAD) and clinical evidence of ischemic heart disease, such as CAD, stable / unstable angina or silent ischemia, need percutaneous coronary intervention.
- •Angiographic Inclusion Criteria
- •Subject must have de novo or restenotic lesion(s) in native coronary arteries, including in-stent restenosis suitable for percutaneous coronary intervention.
- •A maximum of two lesions that needed to be treated and they are located in two coronary arteries, including at least one target lesion, in up to two coronary arteries.
- •Target lesion must have a reference vessel diameter (RVD) between 1.75 and 4.0 mm by visual estimation.
- •Target lesion(s) must have a diameter stenosis of ≥70% by visual estimation.
- •The non-target lesion must be located in different coronary artery from the Target lesion. Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion and must be deemed a clinical angiographic success as visually assessed by the physician.
排除标准
- •STEMI or NSTEMI within 7 days of study screening.
- •A serum creatinine level > 2.0 mg/dl within 7 days prior to index procedure.
- •Cerebrovascular accident (CVA) within the past 6 months.
- •Active peptic ulcer or active gastrointestinal (GI) bleeding within the past 6 months.
- •Left ventricular ejection fraction (LVEF) <30% (LVEF may be obtained at the time of the index procedure if the value is unknown, if necessary)
- •Subject with a known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, anti-platelet medications,
- •Subject is known to be allergic to the ingredients of the test product and the sensitivity to contrast media.
- •Subject with known pregnancy or is nursing. Women of child-bearing potential should have a documented negative pregnancy test within 7 days before index procedure.
- •Planned or actual target lesion treatment with an unapproved device, atherectomy, laser, cutting balloon or thrombectomy during the index procedure.
- •Subjects who are participating in clinical research of other drugs and devices.
- •Other conditions assessed by the investigator as inappropriate to participate in this trial.
- •Angiographic Exclusion Criteria
- •Target lesion longer than 30 mm by visual estimation.
- •Extreme angulation (90º or greater) proximal to or within the target lesion.
- •Target lesion located within an arterial or saphenous vein graft or graft anastomosis
- •Previous percutaneous intervention of lesions in a target vessel (including side branches) conducted within 9 months before the study procedure and located within 10 mm from the current target lesion.
- •Target lesion demonstrating severe dissection prior to planned deployment of the investigational device.
- •Unprotected left main coronary artery disease.
- •Coronary artery spasm of the target vessel in the absence of a significant stenosis.
- •Target lesion with angiographic presence of probable or definite thrombus.
- •Target lesion involves a bifurcation requiring treatment with more than one stent or pre-dilatation of a side branch >2.0 mm in diameter.
- •Non-target lesion to be treated during the index procedure meets any of the following criteria:
- •Located within a bypass graft (venous or arterial)
- •Left main location
- •Chronic total occlusion
- •Involves a bifurcation (e.g., bifurcations requiring treatment with more than 1 stent)
- •Treatment not deemed a clinical angiographic success
结局指标
主要结局
Rate of device Procedural Success
时间窗: Peri-procedural (at Day 0)
Device procedural success consisting of the following: * Successful delivery, inflation, deflation, and withdrawal of the device * No evidence of vessel perforation, flow limiting dissection (grade C or higher) or reduction in Thrombolysis In Myocardial Infarction (TIMI) flow from baseline as related to the devices * Residual stenosis of target lesion \<50% after balloon angioplasty, Final TIMI flow grade of 3 at the conclusion of the percutaneous coronary intervention (PCI) procedure
次要结局
- Improvement in Minimum Lumen Diameter (MLD) following use of Scoreflex NC catheter (measured by QCA).(Peri-procedural (at Day 0))
- In-hospital Major Adverse Cardiac Events (MACE)(Endpoints will be measured through hospital discharge (expected to be within 24 hours))
- Device-oriented target lesion failure (TLF)(30 days)
- Patient-oriented composite endpoint(30 days)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Scoreflex NC - Scoring PTCA CatheterCoronary DiseaseCoronary Artery DiseaseHeart DiseasesCardiovascular DiseasesArteriosclerosisMyocardial IschemiaNCT03763747OrbusNeich200
已完成
不适用
Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal FailureAcute Renal FailureNCT01072682SeaStar Medical35
招募中
1 期
SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaHead and Neck Squamous CarcinomaNCT05552807Sinocelltech Ltd.120
已完成
不适用
TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial FibrillationParoxysmal Atrial FibrillationNCT03354663Abbott Medical Devices156
已完成
3 期
CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System EvaluationCoronary DiseaseNCT00422435Conor Medsystems107